Value of Second-Generation TKIs Must Be Considered for CML Patients

Researchers looked at second-generation tyrosine kinase inhibitors at their current prices to test treatment value for patients with chronic myeloid leukemia.

Source: CancerNetwork - June 24, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news